RVMD News

Investors Urged to Contact Levi & Korsinsky for Information Before August 10, 2026 - Erasca, Inc. (ERAS)

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against Erasca, Inc. (ERAS)

Join Class Action to Recover Losses from Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026

Join Class Action to Recover Losses from Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026

Recover Investment Losses: Class Action Initiated Against Erasca, Inc. (ERAS)

Securities Fraud Class Action Filed Against Erasca, Inc. (ERAS) - Levi & Korsinsky Reminds Investors of August 10, 2026

ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline

ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against Erasca, Inc. (ERAS)